American Academy of Neurology 2022: Multiple Sclerosis Highlights

Robert Zivadinov, MD, PhD, offers his insight into the findings from the DeepGRAI registry of thalamic volume measurement on multicenter clinical-quality T2-FLAIR images in multiple sclerosis.

Stephen Krieger, MD, spoke about the latest safety data on ofatumumab (Kesimpta; Novartis) and the progress made in novel therapeutics for multiple sclerosis.

Ludwig Kappos, MD, FEAN, FAAN, provided insight on a new analysis that showed greater proportions of patients achieving no evidence of disease activity on ozanimod compared with interferon ß-1a.

Robert K. Shin, MD, offered his perspective on the novel therapies being developed for multiple sclerosis, highlighting the potential of Bruton tyrosine kinase inhibitors for progressive disease.

Bruce Cree, MD, PhD, MAS, FAAN, shared his thoughts on the data from the ULTIMATE I and II studies of ublituximab's effect on measures of MS disability, including EDSS and 9HPT scores.

Stephen Krieger, MD, spoke about the phase 3b NOVA study (NCT03689972) data presented at AAN 2022 on natalizumab (Tysabri; Biogen) dosing regimens.

Discussing the progress made in therapeutic approaches to multiple sclerosis, Robert K. Shin, MD, shared his perspective on how the focus on treatments has shifted in the community.

Robert Zivadinov, MD, PhD, discusses the design of a novel comparative study assessing the effect of siponimod (Mayzent; Novartis) and ocrelizumab (Ocrevus; Genentech) on microglia and astrocytes in patients with SPMS.